Samlyn Capital’s Amgen AMGN Stock Holding History

Samlyn Capital’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-458,000	Closed	-$67M	–	139
2016 Q4	$67M	Buy	458,000 +313,500	+217%	+$47.2M	1.52%	22
2016 Q3	$24.1M	Buy	+144,500	New	+$24.4M	0.57%	69

Other funds holding AMGN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Samlyn Capital's AMGN Position: Q1 2017 in Review

Samlyn Capital sold out of Amgen (AMGN) in Q1 2017, closing a stake of 458,000 shares — an estimated $67M sold.

Samlyn Capital first reported a position in AMGN in Q3 2016 and held it in 2 quarters. The position peaked at $67M in Q4 2016. 1,601 funds tracked by Wall St. Rank hold AMGN as of Q1 2017.

Samlyn Capital reported no remaining Amgen position as of Q1 2017 after selling out during the quarter.
Samlyn Capital sold 458,000 Amgen shares in Q1 2017, an estimated $67M.
Samlyn Capital first reported a position in Amgen in Q3 2016 and held it in 2 quarters.
Samlyn Capital's Amgen position peaked at $67M in Q4 2016.
1,601 funds tracked by Wall St. Rank held Amgen as of Q1 2017.

Based on Samlyn Capital's 13F filing for Q1 2017, filed 15 May 2017.